EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Parasympathicolytic drugs in treatment of obstructive lung diseases


Deutsche Medizinische Wochenschrift 104(31): 1098-1104
Parasympathicolytic drugs in treatment of obstructive lung diseases
In order to investigate the effect of ipratropium bromide in antigen induced bronchial obstruction 8 series of investigations were performed in patients with extrinsic asthma using bronchial provocation tests. The broncholytic effect of ipratropium bromide (0.1 and 0.25 mg in 1 ml solution) was significantly lower when compared with fenoterol and salbutamol and not clearly distinct from untreated controls, when airway resistance, thoracic gas volume and specific airway resistance were measured. No correlation of the effect of ipratropium bromide with bronchial reactivity to histamine, basal values and antigen induced obstruction as well as corticosteroid dependency could be ascertained. Increase of dosage did not lead to improved effectiveness. In contrast protective application of ipratropium bromide before antigen inhalation led to prevention of obstructions did disodium cromoglycate. It is concluded that regular prophylactic application of ipratropium bromide is more effective than bronchospasmolytic application. All forms of obstructive pulmonary disease are thus an indication for parasympathicolytic drugs provided they are used regularly.


Accession: 038964872

PMID: 37060



Related references

Antileukotriene drugs in the treatment of obstructive lung diseases and rhinitis. Pneumonologia i Alergologia Polska 78(1): 74-78, 2010

Evaluation of drugs for the treatment of chronic obstructive lung diseases--analysis of bronchospasmolytics/antiasthmatics of the Red List 1984. Praxis und Klinik der Pneumologie 39(12): 957-961, 1985

Tucson epidemiologic study of obstructive lung diseases part 2 effects of in migration factors on the prevalence of obstructive lung diseases. American Journal of Epidemiology 102(2): 153-163, 1975

Tucson epidemiologic study of obstructive lung diseases. II: Effects of in-migration factors on the prevalence of obstructive lung diseases. American Journal of Epidemiology 102(2): 153-163, 1975

Differential diagnosis of bronchial asthma and chronic obstructive lung diseases. Current recommendations for the treatment of bronchial asthma and chronic obstructive lung diseases. Terapevticheskii Arkhiv 67(12): 66-71, 1995

Use of spirometry and respiratory drugs in Manitobans over 35 years of age with obstructive lung diseases. Canadian Respiratory Journal 12(2): 69-74, 2005

Chronic-obstructive lung diseases. The treatment of chronic-obstructive lung diseases with transbronchin. Zfa. Zeitschrift für Allgemeinmedizin 54(21): 1099-1102, 1978

Air-pollution and respiratory diseases. Therapy: treatment of obstructive lung diseases in the air-polluted area. Nihon Kyobu Shikkan Gakkai Zasshi 11(12): 736-741, 1973

The characteristics of the clinical course and treatment of chronic obstructive lung diseases against a background of lymphoproliferative diseases. Terapevticheskii Arkhiv 69(3): 19-23, 1997

Value of vasodilator agents in the treatment of diseases with pulmonary hypertension caused by chronic obstructive lung diseases. Pneumonologia i Alergologia Polska 59(3-4): 153-158, 1991